Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up

References

• Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 2011;378:2104–11.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, D’Amico AV. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 2008;26: 2055–6.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, et al. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011; 187:479–84.
   PubMed Web of Science ®Google Scholar
• Morikawa LK, Roach M, III. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: Evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 2011;80:6–16.
   PubMed Web of Science ®Google Scholar
• Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fossa S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009; 10:370–80.
   PubMed Web of Science ®Google Scholar
• Lips I, Dehnad H, Kruger AB, van MJ, van der HU, Battermann J, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007;69:656–61.
   PubMed Web of Science ®Google Scholar
• Pervez N, Krauze AV, Yee D, Parliament M, Mihai A, Ghosh S, et al. Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression. Curr Oncol 2012;19:e201–10.
   Web of Science ®Google Scholar
• Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2009;75:1344–9.
   PubMed Web of Science ®Google Scholar
• Sridharan S, Warde P. The importance of local control in high-risk locally advanced prostate cancer. Curr Oncol 2012;19:S6–12.
   PubMed Web of Science ®Google Scholar
• Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:685–91.
   PubMed Web of Science ®Google Scholar
• Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003;4:233–41.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Stensvold A, Dahl AA, Brennhovd B, Smastuen MC, Fossa SD, Lilleby W, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol 2013;31: 1067–78.
   PubMed Web of Science ®Google Scholar
• Lilleby W, Stensvold A, Dahl AA. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: A study of adverse effects and their relation to quality of life. Prostate 2013;73: 1038–47.
   PubMed Web of Science ®Google Scholar
• Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002;94: 2511–6.
   PubMed Web of Science ®Google Scholar
• Roach M, III, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. Defining high risk prostate cancer with risk groups and nomograms: Implications for designing clinical trials. J Urol 2006;176: S16–20.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163–72.
   PubMed Web of Science ®Google Scholar
• Berg A, Lilleby W, Bruland OS, Fossa SD. 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1074–83.
   PubMed Web of Science ®Google Scholar
• Stensvold A, Dahl AA, Fossa SD, Axcrona K, Lilleby W, Brennhovd B, et al. Clinicians’ use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncol 2011;50:408–14.
   PubMed Web of Science ®Google Scholar
• Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002–12.
   PubMed Web of Science ®Google Scholar
• Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
   PubMed Web of Science ®Google Scholar
• Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res 1993;37:147–53.
   PubMed Web of Science ®Google Scholar
• Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: Normative data and associations. J Psychosom Res 1998;45:53–65.
   PubMed Web of Science ®Google Scholar
• Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1171–8.
   PubMed Web of Science ®Google Scholar
• Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short- Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34: 220–33.
   PubMed Web of Science ®Google Scholar
• Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, et al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010;183:1822–8.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar
• Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fossa SD, Lilleby W, et al. Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate 2012;72:668–76.
   PubMed Web of Science ®Google Scholar